Club Femina is the blog made for, by and about women including business, education, entertainment, health, motherhood, recreation and politics
November 25th, 2008 by Femina

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

The National Crime Prevention Council says travel safety has taken on a new meaning during these tough economic times. The organization best known for its icon, McGruff the Crime Dog, says opportunistic thieves may be looking for unprotected homes or pre-occupied travelers during the Thanksgiving holiday.

NCPC suggests following these safety tips to avoid problems during the start of the busiest travel season of the year.

Safety begins at home

  • Make sure your house looks “lived-in” when you are away. Lock all doors and windows, and set household lights (inside and out) on timers.
  • Trim your hedges and bushes so thieves do not have a place to hide out.
  • Have a neighbor park a car in your driveway to make it appear as if someone is home.
  • Invest in an alarm. An alarm system controls access points to your home and lets you know if someone has invaded your space.
  • Ask a trusted neighbor or friend to watch your house and pick up your mail and newspapers while you are away.
  • File a “travel plan.” Let someone know where you are going, the route you plan to take, and when you plan to arrive. If you deviate from that plan, let someone know.

Watch out for clever criminals

  • Do not stop if your car is bumped from behind or if someone says there is something wrong with your car. Go to a service station or a well-lit, populated area and call for help.
  • Fill the gas tank before dark and lock your car doors, and roll up your windows if you step away from the car for any reason.
  • Never leave items of value such as cell phones, cameras, jewelry, or other expensive belongings visible in your car. Lock them in your trunk or take them with you.

Safety away from home

  • Carry money separately from credit cards. Carry your purse close to your body or your wallet inside a coat or front trouser pocket.
  • If you choose to shop on Black Friday, do not overburden yourself with packages to avoid being an easy target.
  • Stick to well-lighted and well-traveled streets at all times.
  • Select ATM machines in visible, well-lighted locations.
  • Do not leave valuables in your hotel room. Most hotels have safes for guest use.
  • Keep your hotel room door locked, even when you are inside.

National Crime Prevention Council

The National Crime Prevention Council (NCPC) is a private, nonprofit organization whose primary mission is to be the nation’s leader in helping people keep themselves, their families, and their communities safe from crime. NCPC manages public service advertising under the National Citizens’ Crime Prevention Campaign — symbolized by McGruff the Crime Dog(R) and his “Take A Bite Out Of Crime(R)” slogan — and acts as secretariat for the Crime Prevention Coalition of America, more than 400 national, federal, state, and local organizations representing thousands of constituents who are committed to preventing crime. NCPC is funded through a variety of government agencies, corporate and private foundations, and donations from private individuals. For more information on crime prevention issues, visit www.ncpc.org.

November 23rd, 2008 by Femina

Local Medical Device Company Welcomes Kristin Shumpert to America’s City of Lights … After Changing her Life with Technology

“Thanks to NMT, all of my wishes are coming true,” says Kristin Shumpert, who is traveling from Oak Ridge, Tennessee this week to experience the lights, sounds and excitement of Las Vegas … and to meet the people who “saved my life.” Until recently, the prospect of spending time far from home held little interest to the young woman who suffers from a devastating disorder that affects her ability to regulate thirst or sense when its time to use the ladies’ room.

At the age of 18, Kristin, now 23, underwent surgery on a benign brain tumor, resulting in the removal of her pituitary gland. No larger than the size of a pea and found at the base of the brain, the pituitary gland secretes a hormone known as vasopressin that triggers the kidneys to regulate normal storage and release of bodily fluids. As a consequence of the surgery, Kristin developed Diabetes Insipidus (DI), a type of diabetes much different from the kind brought on by too much sugar in the blood.

Prior to being diagnosed with the condition, Kristin would complain to her mother that she felt like she could not quench her intense thirst, despite drinking an extraordinary amount of fluids. To complicate matters, she had lost the ability to recognize when her body was overhydrated and when it was time to urinate. To treat Kristin, her doctors prescribed nasal vasopressin, which immediately triggers her body to release the fluids. However, not knowing how to regulate her hydration levels, Kristin was often left confused and ultimately found it difficult to stray far from home. “It was dreadfully debilitating and seriously impacted the quality of my life.”

If water intake is seriously impaired, there is a grave risk of severe dehydration that could lead to serious brain damage or even death. On the other hand, overhydration, also referred to as water intoxication, can result in digestive problems, behavioral changes, brain damage, seizures or coma.

Kristin’s mother, Jody Shumpert, works at the Oak Ridge Associated Universities, a consortium of 99 doctoral-granting academic institutions. Earlier this year, Jody read an article regarding Oak Ridge National Laboratories’ (ORNL) research collaboration with Noninvasive Medical Technologies, Inc. (NMT), a Las Vegas-based medical device company pioneering highly advanced, award-winning medical assessment and communications solutions for military and civilian medical use. Aiming to improve the odds for people medically at risk from dehydration or congestive heart failure, ORNL and NMT were actively engaged in improving and miniaturizing NMT’s proprietary, patented ZOE(TM), an FDA-approved noninvasive medical device that monitors a person’s fluid status using bioimpedence. Curious, Jody contacted ORNL to inquire whether or not this technology could potentially help Kristin monitor her hydration levels. After being redirected to NMT’s Chief Operating Officer Ann McCaughan, Jody believed she had found a potential savior for her daughter.

A registered nurse recognized as one of the nation’s leading experts in Cardiac Home Care, McCaughan oversees NMT’s product design and development efforts and has largely been responsible for spearheading the conceptualization and commercialization of the ZOE. After speaking with Jody and learning more about Kristin’s medical condition, McCaughan immediately tasked Carolyn Humphrey, a clinical consultant to NMT, to direct a study to determine whether the ZOE could prove effective for Kristin.

NMT sent Kristin a ZOE fluid status monitor and several sets of electrodes required to measure her hydration levels. Under Humphrey’s direction, she was taught how to self-monitor her “Zo” readings. (Zo, or “Z naught,” is a metric that has been used for years in cardioplethsmograph technology to determine hydration in human subjects.) A series of monitoring days were established, initially beginning in two to three day segments for consistent measuring purposes. There was a need for flexibility in the data collection schedule since Kristin’s DI treatment plan was still being established by her physicians. Moreover, because her brain tumor had reappeared, requiring her to undergo radiation therapy several months before commencing the NMT study, it was essential that she be closely monitored to ensure that the timing of her medications were accurately determined.

Keeping a detailed daily journal, Kristin tracked her fluid intake, when she felt thirsty, the level of her fullness, her physical symptoms and each time she took her nasal vasopressin within a 24-hour period. Through regular conversations with Humphrey, trends emerged from the data that helped to empower Kristin with crucial insight helping her to recognize when to stop drinking fluids (even though she was thirsty) and when to administer her nasal vasopressin to signal her body to urinate. Kristin notes, “With the ability to confidently and objectively measure what’s going on inside me, it is no longer a guessing game. NMT has given me back control of my life!”

Ronald McCaughan, Chairman and CEO of NMT, noted, “NMT has achieved notable advancements in the field of noninvasive hemodynamic assessment and monitoring — advancements some have described as innovative and, even, truly extraordinary. Still others have suggested that our cutting edge product research and development efforts are producing disruptive technologies that will indeed redefine the standard of medical care in our industry. But, it is when we meet people like Kristin that we fully appreciate that the work we are accomplishing at NMT is without question of profound importance.”

In addition to reassuming control over her body, Kristin has long wished to vacation in Las Vegas. NMT made that wish come true, too. The Company has arranged for Kristin and her mother Jody to arrive at Las Vegas McCarran International Airport tomorrow afternoon and be transported to the luxurious Monte Carlo Resort and Casino, where, as NMT’s guests, mother and daughter will be treated to the hotel’s AAA Four Diamond hospitality and a taste of all the excitement and entertainment that has made Las Vegas a destination of choice.

On Monday, Kristin and Jody will arrive at NMT’s offices, where they will be granted a personal tour of the facilities and meet all of the people who have worked so hard to make the ZOE possible. “Having the chance to personally meet Kristin and her mother is a gift to the entire NMT team. It is thrilling to know that it is because of our efforts that someone so young and full of vital energy can now truly enjoy everything that life has to offer her,” added Ann McCaughan. “This is a proud moment for NMT — and a wish that has come true for us.”

Source: Noninvasive Medical Technologies, Inc.

November 14th, 2008 by Femina

Results Presented for Genotyping Tests Now Under Development by QIAGEN

As testing for high-risk types of the human papillomavirus (HPV) emerges as the gold standard in cervical cancer prevention, scientists are already researching how to determine even more precisely who is most likely to develop the disease and thus are in need of more immediate intervention. Speaking at the EUROGIN (European Research Organization on Genital Infection and Neoplasia) conference THIS WEEK, experts presented data suggesting that the most effective strategy would be to introduce a second test to determine if women who test positive for high-risk HPV have one of three types of the virus that are associated with the highest mortality from cervical cancer: 16, 18 and 45.

About 30 HPV types are spread through genital contact, and about 18 of these can potentially cause cervical cancer. Each is “named” with a number, in the order of their discovery. Much attention has been paid to types 16 and 18, which account for 70 percent of all cervical cancers and against which the new HPV vaccines protect. However, experts say that medical evidence shows that type 45 should be a priority concern as well.

“Most of the focus has been on HPV types 16 and 18, because they are the most prevalent carcinogenic HPV types and are targeted by the new HPV vaccines,” comments Attila Lorincz, PhD, one of the originators of the HPV test and Professor at Barts and The London School of Medicine. “However, type 45 also is highly associated with risk, particularly for adenocarcinoma, a very aggressive type of cervical cancer with a mortality rate of 52% after five years — twice the rate of squamous-cell cancers. The incidence of invasive cervical adenocarcinoma, which used to account for 10-15 percent of all cervical cancers, has been steadily increasing — in part because it develops inside the cervical canal and thus is difficult to detect early using a Pap smear.”

Currently, there is one HPV test, developed by QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) and marketed as the digene HPV Test, which is approved by the U.S. Food and Drug Administration and is CE-marked in Europe. When used for screening, it is given to women over the age of 30 along with a Pap test, which can find abnormal cells but cannot detect HPV directly. And now, QIAGEN is developing two types of follow-up tests that will identify specifically which types of the virus are carried by HPV-positive women. At EUROGIN this week, QIAGEN scientists are presenting the results of research showing the accuracy of the company’s digene HPV Genotyping PS Test, which specifically identifies the presence of types 16, 18 and 45. This assay is based on the technology used in QIAGEN’s front-line HPV screening test, hybrid capture 2 (hc2) — currently the gold standard in the field. In addition, data are being presented for a second QIAGEN assay, the digene HPV Genotyping RH Test, which identifies 18 types of potentially carcinogenic HPV. Prior to receiving CE marking in Europe, the genotyping tests will be made available for research use by laboratories and physicians exploring their potential clinical benefits. First to be available will be the digene HPV Genotyping RH Test, which is expected to be launched by the end of this year.

Currently, women who screen positive for high-risk HPV, but have normal Paps, are brought back for re-testing 12 months later, since it is only persistent infections that cause cancer. However, Dr. Lorincz explains that genotyping would allow women with HPV 16, 18 or 45 — who are at highest risk of cervical cancer — to be immediately examined further for the presence of pre-cancerous or cancerous cells.

Source: QIAGEN